Gilead Sciences stock heads into Denver with new liver data

Gilead Sciences plans to present 21 abstracts on rare liver diseases at the Liver Meeting in Denver from November 5 to 9, according to an AD HOC NEWS report published on November 2. The program gives investors a near-term view of pipeline progress beyond the company's HIV franchise.

Gilead said on October 22 that the conference program would cover primary biliary cholangitis and chronic hepatitis D. The company plans to present late-stage Phase 3 findings for Livdelzi, also known as seladelpar, and long-term and real-world analyses for Hepcludex.

What investors will watch

For Livdelzi, the IDEAL study includes results on alkaline phosphatase normalization in adults with primary biliary cholangitis. Additional presentations address safety and efficacy over as long as five years, together with fatigue, quality of life, treatment adherence and possible treatment escalation.

Hepcludex presentations will include 96-week findings on combined virologic and biochemical response. Another analysis covers clinically relevant portal hypertension after 48 weeks, while real-world work addresses low testing rates and the disease burden associated with hepatitis D. The scheduled presentations, rather than the advance announcement, will provide the next substantive clinical readout.

Share price moves since prior report

Gilead Sciences stock traded at 152.54 euros on Lang & Schwarz at 16:08 CET on Tuesday, November 3, 1.23 percent above the Xetra close of Monday, November 2, at 150.68 euros. Compared with the 150.85-euro quote in the November 2 report, the new quote is 1.12 percent higher.

Investors can follow the real-time quote of Gilead Sciences stock. The US market backdrop can be followed through the S&P 500.

More news and analyses on Gilead Sciences stock will depend on the clinical findings presented in Denver.